Revance Therapeutics, Inc.

Historical 13F Holders

Symbol
RVNC
CUSIP
761330109
All holders as of
Q1 2025
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 761330109 since 12/18/2024, largest first.

Filer % of Class Filed
Teoxane SA 13D/A 6.2% 1/30/2025
Event 1/30/2025
Under 5%, checked the "5 percent or less" box, or amended by a later filing (5)
Franklin Resources, Inc. 13G/A
4.6% 10/31/2024
Event 9/30/2024
Palo Alto Investors LP 13G/A
1.5% 2/13/2025
Event 9/30/2024
Beryl Capital Management LLC 13G/A
0% 5/15/2025
Event 3/31/2025
Glazer Capital, LLC 13G/A
0% 5/15/2025
Event 3/31/2025
JPMorgan Chase & Co 13G/A 0% 3/6/2025
Event 2/28/2025

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2025 Q1 2 86.1 k $425k
2024 Q4 183 82.0 M $249M
2024 Q3 210 83.4 M $432M
2024 Q2 177 85.3 M $219M
2024 Q1 191 88.8 M $439M
2023 Q4 199 78.7 M $692M
2023 Q3 192 77.9 M $893M
2023 Q2 217 83.1 M $2.10B
2023 Q1 222 78.6 M $2.53B
2022 Q4 196 75.9 M $1.40B
2022 Q3 188 67.7 M $1.82B
2022 Q2 167 56.0 M $774M
2022 Q1 159 54.6 M $1.06B
2021 Q4 155 53.1 M $867M
2021 Q3 160 54.9 M $1.53B
2021 Q2 162 54.1 M $1.60B
2021 Q1 152 54.8 M $1.53B
2020 Q4 153 53.4 M $1.51B
2020 Q3 156 49.5 M $1.25B
2020 Q2 145 50.6 M $1.23B
2020 Q1 133 49.5 M $732M
2019 Q4 137 51.6 M $838M
2019 Q3 111 42.6 M $554M
2019 Q2 116 43.7 M $566M
2019 Q1 115 41.7 M $657M
2018 Q4 104 35.6 M $741M
2018 Q3 112 34.7 M $863M
2018 Q2 113 35.2 M $965M
2018 Q1 122 34.4 M $1.06B
2017 Q4 118 35.0 M $1.25B
2017 Q3 86 27.4 M $755M
2017 Q2 88 27.5 M $727M
2017 Q1 80 26.4 M $549M
2016 Q4 82 26.3 M $544M
2016 Q3 75 28.6 M $464M
2016 Q2 83 28.8 M $391M
2016 Q1 86 27.3 M $477M
2015 Q4 105 27.2 M $931M
2015 Q3 79 21.7 M $655M
2015 Q2 88 20.5 M $655M
2015 Q1 71 20.6 M $426M
2014 Q4 68 19.8 M $335M
2014 Q3 81 15.7 M $303M
2014 Q2 98 16.7 M $567M
2014 Q1 66 11.9 M $376M